Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel

Annals of Oncology

Volumn 21, Issue 6, 2009, Pages 1315-1322

  Sessa, C ^a,b   Tosi, D ^b   Vigano L ^b   Albanell, J ^c   Hess, D ^d   Maur, M ^a   Cresta, S ^b   Locatelli, A ^b   Angst, R ^d   Rojo, F ^c   Coceani, N ^e   Rivera, V M ^f   Berk, L ^f   Haluska, F ^f   Gianni, L ^b  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c HOSPITAL DEL MAR   (Spain)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e Southern Europe New Drug Organization Foundation   (Italy)

^f ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

Angiogenesis; mTOR inhibitor; Paclitaxel; Phase I; Ridaforolimus

Indexed keywords

CAPECITABINE; DEFOROLIMUS; FLUOROURACIL; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MK 8669; PACLITAXEL; RIDAFOROLIMUS; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ACNE; ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BREAST CANCER; CHEILITIS; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; ECZEMA; EPIDERMIS; ERYTHEMA; FATIGUE; FEMALE; GINGIVA DISEASE; GINGIVA PAIN; GINGIVA SWELLING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIP DISEASE; MALE; MAXIMUM TOLERATED DOSE; MOUTH DISCOMFORT; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PANCREAS CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHARYNX CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN BIOPSY; SKIN EXFOLIATION; SKIN FISSURE; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; ALGORITHM; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG INTERACTION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 73849119080     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp504     Document Type: Article

References (25)

1. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007; 13: 3109-3114.
2. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-734.
3. Cohen EE. mTOR: the mammalian target of replication. J Clin Oncol 2008; 26: 348-349.
4. Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 2005; 10: 479-498.
5. Dancey JE. Therapeutic targets. MTOR and related pathways. Cancer Biol Ther 2006; 5: 1065-1073.
6. Clackson T, Metcalf CA, Rivera VM et al. Broad anti-tumor activity of AP23573, an mTOR inhibitor in clinical development. Proc Am Soc Clin Oncol 2003; 22: 220 (Abstr 882).
7. Mita MM, Mita AC, Chu QS et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008; 26: 361-367.
8. Hartford CM, Desai AA, Janisch L et al. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 2009; 15(14): 1428-1434.
9. Desai AA, Janisch L, Berk L et al. A phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with advanced or refractory malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis. J Clin Oncol 2004; 22 (Suppl): 232 (Abstr 3150).
10. Mita MM, Britten CD, Poplin E et al. Deforolimus trial 106-a phase I trial evaluating 7 regimens of oral deforolimus (AP23573, MK-8669). J Clin Oncol 2008; 26: (5s Suppl): (Abstr 3509).
11. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135.
12. Tan C, Cruet-Hennequart S, Troussard A et al. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 2004; 5: 79-90.
13. Brown NS, Bicknell R. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J 1998; 334: 1-8.
14. Seeliger H, Guba M, Koehl GE et al. Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res 2004; 10: 1843-1852.
15. Sawada N, Ishikawa T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4: 1013-1019.
16. Rivera VM, Tang H, Metcalf CA et al. Anti-proliferative activity of the mTOR inhibitor AP23573 in combination with cytotoxic and targeted agents. Proc Am Assoc Cancer Res 2004; 45: 896-a (Abstr 3887).
17. Pasquier E, Honore S, Pourroy B et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005; 65: 2433-2440.
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
19. Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetic of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180.
20. Rivera VM, Berk L, Mita M et al. Pharmacodynamic evaluation of the mTOR inhibitor AP23573 in phase I clinical trials. Eur J Cancer 2004; 2: 123 (Abstr 123).
21. Tabernero J, Rojo F, Calvo E et al. Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1603-1610.
22. Rojo F, Najera L, Lirola J et al. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 2007; 13: 81-89.
23. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
24. Rizzieri DA, Feldman E, Dipersio JF et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008; 14: 2756-2762.
25. Legrier ME, Yang CP, Yan HG et al. Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res 2007; 67: 11300-11308.